Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
 
00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementLee33%0.67 [0.42-1.08]cases19/1,67495/5,345Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP33%0.67 [0.42-1.08]19/1,67495/5,34533% improvementAll studies45%0.55 [0.31-0.98]27/2,534116/6,21745% improvement3 budesonide COVID-19 studiesc19budesonide.com Sep 20, 2021Tau​2 = 0.08; I​2 = 27.1%; Z = 2.01Effect extraction pre-specifiedFavors budesonideFavors control
Database of all budesonide COVID-19 studies. Submit updates/corrections.
Sep 9
PrEP Lee et al., Research Square, doi:10.21203/rs.3.rs-72221/v1 (Preprint) cases, ↓32.6%, p=0.10 Association Between Inhaled Corticosteroid Use and the Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Nationwide Population-based Study in South Korea
Details   Retrospective 44,968 patients in South Korea, 7,019 on inhaled corticosteroids, showing no statistically significant differences in COVID-19 cases.
Jul 20
In Vitro Heinen et al., Viruses, doi:10.3390/v13071411 (Peer Reviewed) (In Vitro) in vitro Antiviral Effect of Budesonide against SARS-CoV-2
Details   In Vitro study showing dose-dependent inhibition of SARS-CoV-2 with budesonide.
May 5
In Vitro Konduri et al., bioRxiv, doi:10.1101/2021.05.05.442779 (Preprint) (In Vitro) in vitro ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
Details   In Vitro study and animal study showing that ProLung™-budesonide inhibits SARS-CoV-2 replication (results for budesonide were not provided). ProLung™-budesonide and budesonide significantly decreased lung inflammation. ProLung™-budesonide..
Apr 12
Late Yu et al., The Lancet, doi:10.1016/S0140-6736(21)01744-X (preprint 4/12/21) (Peer Reviewed) death, ↓39.1%, p=0.45 Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
Details   Interim results from the PRINCIPLE trial, 1,073 treated with budesonide starting a median of 6 days after symptom onset, showing lower hospitalization/death, and faster recovery with treatment. ISRCTN86534580.
Feb 8
Early Ramakrishnan et al., Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00160-0 (preprint 2/8) (Peer Reviewed) hosp./ER, ↓81.8%, p=0.02 Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
Details   RCT with 73 budesonide patients and 73 control patients, showing significantly lower combined risk of an ER visit or hospitalization, and lower risk of no recovery at day 14.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit